Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for talimogene laherparepvec

  1. Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

    Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA410

  2. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development

  3. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

    Technology appraisal guidance
    Discontinued

  4. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

    NICE guideline
    Last updated
    27 July 2022
    View recommendations

    Sections for NG14